A Rapid and Sensitive Test for Diagnosing Heparin-Associated Thrombocytopenia

Summary

Heparin-associated thrombocytopenia (HAT) is a severe complication of heparin therapy. Its diagnosis is difficult. Conventional assays employ platelet aggregometry (PAA) and/or ¹⁴C-serotonin release (SRA) which are either insensitive (PAA) or require radioactive tracers (SRA). We here describe a newly developed sensitive and rapid assay based on visual evaluation of heparin-induced platelet activation (HIPA) in microtiter wells. Using sera of 34 patients with clinically suspected HAT we found the HIPA assay to be as sensitive as the SRA and superior to PAA. The HIPA assay allows investigation of crossreactivity with different types of heparins, low molecular weight (LMW) heparins and heparinoids. Three patients who required further parenteral anticoagulation and in whom the HIPA assay was negative before treatment with the LMW heparinoid Org 10172, were treated with this new heparinoid without adverse reactions. We conclude that the HIPA assay may be a useful tool for differential diagnosis and therapy in patients with HAT.

• References

• 1 Kelton JG. Heparin-induced thrombocytopenia. Haemostasis 1986: 173-86
• 2 Ansell JE, Price JM, Shah S, Beckner RR. Heparin-induced thrombocytopenia. What is its real frequency? Chest 1985; 88: 878-82
• 3 Bailey RT, Ursick JA, Heim KL, Hilleman DE, Reich JW. Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin. Drug Intell Clin Pharm 1986; 20: 374-8
• 4 Green D, Martin GJ, Shoichet SH, DeBaker N, Bomalaski JS, Lind RN. Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin. Am J Med Sci 1984; 288: 60-4
• 5 Godal HC. Report of the International Committee on Thrombosis and Haemostasis. Thrombocytopenia and heparin. Thromb Haemostas 1980; 43: 222-4
• 6 Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M. Heparin-associated thrombocytopenia: A prospective evaluation of 211 patients. Ther Drug Monit 1983; 5: 205-11
• 7 Laster JL, Nichols K, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern Med 19 149: 2285-7
• 8 Kapsch D, Silver D. Heparin-induced thrombocytopenia with thrombosis and hemorrhage. Arch Surg 1981; 116: 1423-7
• 9 Leroy J, Leclerc MH, Delahousse B, Guerois C, Foloppe P, Gruel Y, Toulemonde F. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin. Semin Thromb Hemostas 1985; 11: 326-9
• 10 Horellou MH, Conard J, Lecrubier C, Samana M, Roque-D'Orbcastel O, de Fenoyl O, Di Maria G, Bernadou A. Persistent heparin-induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemostas 1984; 51: 134
• 11 Blockmans D, Bounameaux H, Vermylen J, Verstraete M. Heparin-induced thrombocytopenia. Platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities. Thromb Haemostas 1986; 55: 90-3
• 12 Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocy-topenia: confirmation of diagnosis with in vitro-methods. Blood 1975; 45: 395-401
• 13 Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58: 53-7
• 14 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med 1989; 40: 31-44
• 15 Chong BH, Grace CS, Rozenberg MC. Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets. Br J Haematol 1981; 49: 531-40
• 16 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30
• 17 Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984; 103: 606-12
• 18 Meuleman DG, Hobbelen PMJ, van Dedem G, Moellzer HCT. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-63
• 19 Meuleman DG. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models. Semin Thromb Hemostas 1989; 15: 370-2
• 20 Sachs L. Applied Statistics. A Handbook of Techniques.. Springer, New York: 1982
• 21 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Farreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
• 22 Kelton JG, Sheridan D, Santos A, Smith J. et al. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988; 72: 925-30
• 23 Pfueller SL, David R. Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. Br J Haematol 1986; 64: 149-59
• 24 Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 235-40
• 25 Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581-9
• 26 Malik M, Collins J, Ludorf M, Taylor R, Anderson J, Aster RH, McFarland J. Laboratory confirmation of heparin associated thrombocytopenia (HAT). Blood 1989; 74: 24